key: cord-1030373-qgc5t10x authors: Najar Nobari, Niloufar; Seirafianpour, Farnoosh; Dodangeh, Milad; Sadeghzadeh‐Bazargan, Afsaneh; Behrangi, Elham; Mozafarpoor, Samaneh; Goodarzi, Azadeh title: A systematic review of the histopathologic survey on skin biopsies in patients with Corona Virus Disease 2019 (COVID‐19) who developed virus or drug‐related mucocutaneous manifestations date: 2021-05-24 journal: Exp Dermatol DOI: 10.1111/exd.14384 sha: f03085a3eef52d0fa16e9f444aea93827f2cd08b doc_id: 1030373 cord_uid: qgc5t10x The mucocutaneous manifestations of Corona Virus Disease 2019 (COVID‐19) logically may reflect systemic visceral involvements. These findings are visible and easy to approach like biopsies for exact histopathologic evaluations. This systematic review was conducted to collect the mucocutaneous histopathologic data of COVID‐19 patients for future investigations and interpretations. The COVID‐19 dermatology resource of the Centre of Evidence‐Based Dermatology (CEBD) at the University of Nottingham, PubMed, Scopus, Google Scholar and Medscape was searched for relevant English articles published by June 3, 2020. This review included 31 articles, involving 459 patients. The common primary virus‐related mucocutaneous manifestations are easy to approach in the course of COVID‐19. The authors of this study supposed dermatopathological findings as the predictors of the nature of potential systemic involvements and outcomes of COVID‐19. Scrutinizing these findings can help with adopting more effective therapeutic and management strategies; nevertheless, this review found the severity and time of onset of symptoms not to be associated with the laboratory and histopathological findings. Deterioration of clinical conditions and laboratory tests was also not related to the histopathological findings. It is recommended that meta‐analyses be conducted in the future to detail on these data for having more comprehensive and better conclusion. COVID-19 has just appeared in the world and has caused various symptoms in patients. These symptoms include skin manifestations. These skin symptoms may be caused by viruses or drug reactions taken by the patient during the illness. COVID-19 was found to cause storms in viral-host immune interactions and affect the skin and visceral compartments. Mucocutaneous manifestations can reflect pathologic events such as internal organ involvements during infection with SARS-CoV-2 as in the case of many other systemic disorders. As in the case of other viral disorders, SARS-CoV-2 can frequently cause morbilliform, exanthematous, maculopapular or urticarial eruption, which is quite expectable in adults, [1] [2] [3] [4] [5] [6] [7] [8] infants and children. 9, 10 The other skin manifestations included dermatitis herpetiformis, varicella-like exanthem, pityriasis rosea and petechiae [11] [12] [13] [14] as well as mucosal involvements such as aphthous ulcers or conjunctivitis. 1, 15 The abnormal primary cutaneous manifestations in viral disorders frequently reported in COVID-19 patients include "COVID toes" as acral vasculopathic rashes that clinically resemble chilblains or perniosis, [16] [17] [18] [19] acral and digital ischaemia, [20] [21] [22] papulosquamous eruption, 23 petechiae 24 and livedo reticularis. 25 These manifestations suggest a coronavirus pathomechanism that differs from that of similar respiratory-associated viruses, as this virus is not limited to few organs and the virus-related consequences can involve almost all vital organs. The potentially exclusive skin manifestations of COVID-19 such as thrombotic vasculopathy or vasculitis [19] [20] [21] [22] can involve visceral tissues and cause acute respiratory distress syndrome (ARDS) and organ failure. Also, the drugs used to treat COVID-19 could have several side effects, such as mucocutaneous drug reactions; morbilliform/exanthematous maculopapular rashes, urticarial eruptions and AGEP are most types of skin drug reactions that are usually managed by steroids during few days. 26 Hydroxychloroquine and lopinavir/ritonavir are the most prevalent used drugs with the highest skin adverse reaction. 26 So, mucocutaneous drug reactions should be considered in any prescription treatment. Exclusion criteria were reviews, animal studies, COVID-19 articles without mucocutaneous manifestations, COVID-19 articles with mucocutaneous manifestation without a histopathological biopsy. PubMed, Scopus, Google Scholar, Medscape and the COVID-19 dermatology resource of the CEBD at the University of Nottingham (https://www.notti ngham.ac.uk/), that is the link of skin manifestations of coronavirus, were searched for the articles published by June 3, 2020 using the following terms: "COVID-19" OR "severe acute respiratory syndrome coronavirus 2" AND "Skin " OR "Mucosa" OR "Cutaneous" OR "Skin Manifestations" OR "Dermatology" OR "Pathology" OR "Histopathology" OR "Histopathologic" OR "Histology" OR "Biopsy." Endnote® X9 (Clarivate Analytics, Philadelphia, USA) was used for study screening and data extraction. Reviewers assigned each study to the inclusion and exclusion groups. They read the titles and abstracts, and if doubted, have evaluated the full text. Then they read the full text for the inclusion process. Disagreement situations regarding the inclusion process resolved through dialogue, and no necessity for a third-party involvement occurred. In Figure 1 , PRISMA flow diagram was shown. Finally, the interpretation of data is the experts' interpretation, which is achieved through discussion with each other. The experts were professors of dermatology and dermatopathology who have published numerous articles on COVID-19 and have worked together for many years. Reviewers extracted data, filled a pre-designed spreadsheet containing the following information for each study: the article title, MD and FS used two risk assessment tools for the studies that include in this study. The first risk bias assessment tool used in this study was the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I), 28 which is a list of seven domains. The first two domains of ROBINS-1 are about the selection of participants. The third domain is about classification. The other four domains address issues after the start of interventions: biases due to deviations from intended interventions, missing data, measurement of outcomes and selection of the reported result. The second tool that we used for the methodological quality and synthesis of the case reports and case series was a new bias assessment tool that was suggested by Murad et al. 29 The bias assessment tool has four domains of Selection, Ascertainment, Causality and Reporting. The tool also has eight questions that each question has one score. MD and FS separately examined 31 articles that were included in the systematic review study. Disagreement situations regarding the inclusion process resolved through dialogue and no necessity for a third-party involvement occurred. Details of the 459 patients presented in " Table 1 The study mostly had a high/unclear risk of bias in each domain. In the selection section, most case report studies that include in the systematic review have few cases, and it does not provide scoring capability in this section. But on the other hand, in the report section, the vast majority of studies had good results. And they got a good score. In general, the risk of bias of articles was generally unclear. So, more research and article in this field will help to have better conclusions. Based on studies, atypical features were reported in the histopathologic examinations of the patients with morbilliform or exanthematous rashes. 57 It is thoroughly recommended that further studies be conducted using the coagulation profiles of retiform purpura, cyanosis, skin bullae, livedoid vasculopathy and necrotic skin ulceration. 19, 51, 57 In autopsies, usually inflammatory immune-mediated or iatrogenic histologic findings are more prominent than viral cytopathic effects and to somehow comparable with skin biopsies that are the confirmatory data regarding focussing more on the immunomodulatory strategies for disease control. 60 Laboratory tests showed lymphopenia and elevated CRP and D-dimer levels to be the most frequent findings in the patients. The other laboratory findings in peripheral blood counts included leukocytosis, eosinophilia and thrombocytopenia. Slight increases were also observed in liver enzymes and blood fibrinogen levels in some patients, while laboratory findings were normal or unreported in a small group of patients. Moreover, most patients were positive for PCR and only a few were negative. The The authors of this study in overall focussed on the disease pathomechanism, the effects of multi-potential drugs on COVID-19 19 and COVID-related specific comorbidities especially its mucocutaneous manifestations and significant dermatologic considerations in the pandemic area. [66] [67] [68] In conclusion, the visible skin rashes which about In this review, we had several limitations. One of the limitations of this study is just the inclusion of English studies in it, and the Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases A distinctive skin rash associated with Coronavirus Disease A Case of COVID-19 pneumonia in a young male with full body rash as a presenting symptom Morbilliform exanthem associated with COVID-19 Eruption as a clinical manifestation of COVID-19: Photographs of a patient SARS-CoV-2 infection presenting as a febrile rash Urticarial eruption in COVID-19 infection Urticarial exanthem as early diagnostic clue for COVID-19 infection Infants born to mothers with a new coronavirus (COVID-19) Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019) Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: a diagnostic clue? COVID-19 can present with a rash and be mistaken for dengue": petechial rash in a patient with COVID-19 infection COVID-19 can present with a rash and be mistaken for dengue A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East Chilblainlike lesions on feet and hands during the COVID-19 pandemic Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Acral cutaneous lesions in the time of COVID-19 Acute acro-ischemia in the child at the time of COVID-19 Coagulopathy and antiphospholipid antibodies in patients with Covid-19 Digitate papulosquamous eruption associated with severe acute respiratory syndrome coronavirus 2 infection Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection A dermatologic manifestation of COVID-19: transient livedo reticularis A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients Clinical and histopathological study of skin dermatoses in patients affected by COVID-19 infection in the Northern part of Italy ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions Methodological quality and synthesis of case series and case reports A clinicopathological study of 8 patients with COVID-19 pneumonia and a late-onset exanthema Acral cutaneous lesions in the time of COVID-19 Acral purpuric lesions (erythema multiforme type) associated with thrombotic vasculopathy in a child during the COVID-19 pandemic Acro-ischaemia in hospitalized COVID-19 patients Cutaneous lesions in a patient with COVID-19: are they related? Chilblains is a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France Chilblains in children in the setting of COVID-19 pandemic Chilblain-like lesions in children following suspected COVID-19 infection Cutaneous clinicopathological findings in three COVID-19-positive patients observed in the metropolitan area of Clustered cases of acral perniosis: clinical features, histopathology, and relationship to COVID-19 Dermatologic findings in 2 patients with COVID-19 Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings Cutaneous manifestations in COVID-19: a first perspective COVID-19) infection-induced chilblains: a case report with histopathologic findings A late-onset widespread skin rash in a previous COVID-19-infected patient: viral or multidrug effect? Histologic features of long-lasting chilblain-like lesions in a paediatric COVID-19 patient Novel outbreak of acral lesions in times of COVID-19: a description of 74 cases from a tertiary university hospital in Spain Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection SARS-CoV-2 infection presenting as a febrile rash Skin manifestations of COVID-19 Cutaneous small vessel vasculitis secondary to COVID-19 infection: a case report Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19 Unique skin manifestations of COVID-19: is drug eruption specific to COVID-19? Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital Histological pattern in COVID-19-induced viral rash Acute generalized exanthematous pustulosis with erythema multiforme-like lesions in a COVID-19 woman Drug-induced vasculitis in a patient with COVID-19 Skin manifestations of COVID-19 Cutaneous manifestations in COVID-19: a new contribution Histopathological study of a broad spectrum of skin dermatoses in patients affected or highly suspected of infection by COVID-19 in the Northern Part of Italy: analysis of the many faces of the viral-induced skin diseases in previous and new reported cases Autopsy in suspected COVID-19 cases Pathological findings of COVID-19 associated with acute respiratory distress syndrome Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19) Cutaneous side-effects of the potential COVID-19 drugs Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? A systematic review Geriatric challenges in the new coronavirus disease-19 (COVID-19) pandemic: a systematic review Histopathologic survey on lung necropsy specimens of 15 patients who died from COVID-19: a large study from Iran with a high rate of anthracosis A comprehensive review on COVID-19 infection and comorbidities of various organs Histopathologic changes and cellular events of organs systems in COVID-19 Systemic retinoids in the COVID-19 era -are they helpful, safe, or harmful? A comprehensive systematized review Cytokine storm and probable role of immunoregulatory drugs in COVID-19: a comprehensive review Skin manifestations as potential symptoms of diffuse vascular injury in critical COVID-19 patients A systematic review of the histopathologic survey on skin biopsies in patients with COVID-19) who developed virus or drug-related mucocutaneous manifestations NNN and AG performed the research; NNN, AG and FS designed, searched and wrote the study; ASB, EB and SM edited the paper; AG, MD and FS revised the paper; MD and FS implemented the quality assessment. AG submitted the paper.All authors have read and approved the final manuscript and guarantee the accuracy of the manuscript. All members of this research team reviewed the manuscript and data and assume full responsibility for the content. Data is available in the text and table. As this paper is a review article.